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Germ cell tumours (seminoma and nonseminomatous germ cell
tumours (NSGCT)) of the testis are relatively uncommon,
accounting for only 1% of cancers in men, however they are the
commonest tumours in young men (15–35 y) and the incidence is
rising (Mead, 1995). Although the treatment pathways differ in
both groups the overall prognosis is good. Differences in therapy
are related to the biological behaviour and metastatic potential of
the different tumour types.
Patients with metastatic disease frequently have residual masses
following treatment and the management of these masses remains
problematic. If there were persistent malignant disease then imme-
diate surgery or radiotherapy would be indicated. More frequently,
the masses consist of necrotic/fibrotic tissue which can be safely
observed or, in the case of NSGCT, residual benign teratoma
which may be removed as a planned procedure. While anatomical
imaging with computerised tomography (CT) clearly identifies
residual masses it is unhelpful in determining whether the mass
contains residual disease. The measurement of serum tumour
markers may be an indicator of persistent disease but unfortu-
nately these are not sensitive or specific enough and cannot indi-
cate the specific site of the disease relapse (Mostofi et al, 1990;
Javadpour, 1992).
Functional imaging methods (radiolabelled antibodies, gallium-
67 and thallium-201) have been used to determine disease pres-
ence (Kalofonos et al, 1990; Uchiyama et al, 1994; Warren, 1995)
in patients with testicular tumour. In this study we have explored
the use of 18F fluorodeoxyglucose (FDG) positron emission
tomography (PET) to identify active disease by metabolic activity
rather than anatomical size. Potentially this approach could: detect
small volume disease in solitary residual masses or in lymph nodes
that are not enlarged by CT criteria; identify which mass is the site
of recurrence when the patient has multiple residual masses and
identify additional sites unrelated to the known masses. These
techniques could therefore impact on clinical decisions deter-
mining the type of intervention required.
MATERIALS AND METHODS
This study represents a retrospective review of FDG PET scans
performed in a series of consecutive patients with germ cell
tumours between 1994–1998. All patients were referred by clin-
ical oncologists on clinical grounds. The patient group includes
patients with their first relapse and patients who have had a
number of relapses and were chemoresistant.
PET scan protocol
Patients were injected with 320 MBq of 18F FDG following a 6
hour fast and consecutive 5 minute images from the vertex to mid
thigh were obtained on a Siemens ECAT 951 scanner. The images
were reconstructed with a spatial resolution of 8 mm FWHM and
displayed as projection and coronal, transaxial and sagittal images.
Some patients had two position local emission scans over an axial
field of view of 10.8 cm each. In these corresponding transmission
images were acquired at the start or finish of scanning using 68 Ge
rods to enable attenuation correction. All scans were reviewed
independently by 2 Nuclear Medicine Physicians and a consensus
report was issued.
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and the reports issued by the radiologist used to define disease
extent. They were reviewed post PET scan and prior to any further
treatment.
Tumour markers
The serum tumour markers bHCG and aFP were measured at 
the time of the PET scan. The markers measured were bHCG
(abnormal results were bHCG > 5 ku/l) and aFP (abnormal results
were aFP > 8 u/l).
Follow-up
Where possible FDG PET results were correlated with
histopathology, clinical examination and other imaging modalities
to the time of progression, death or to a minimum of 18 months
post FDG PET scanning. Without histopathological confirmation,
absence of tumour was assumed if there was no progression of the
CT abnormalities or that the CT remained or returned to normal
and the patient remained well. Active tumour was assumed if there
was progression of the known lesion or new lesions identified on
conventional imaging during the follow up period.
Mature teratoma differentiated has been regarded as a benign
tumour for the purposes of the FDG PET imaging and therefore if
FDG PET scans were positive this was regarded as a false positive
and if they were negative this was regarded as a true negative.
RESULTS
Seventy FDG PET scans were performed in 55 men who had
separate index events of possible relapse for histologically proven
germ cell tumour. The mean age was 30 years (15–55 y). Forty
seven scans were performed for assessment of residual masses of
which 18 also had raised markers and 23 scans for elevated
markers alone with normal or long-term stable disease on CT.
Residual masses
39 patients (13 seminomas, 24 NSGCT and 2 mixed) had forty-
seven FDG PET scans performed to assess residual masses. These
patients had either single (23/47) or multiple (24/47) sites of
residual masses identified on CT scans.
FDG PET positive patients
Twenty-six of the 47 scans were FDG PET positive in one or more
sites. Twenty-five of these had convincing evidence of disease
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Table 1 Patients with residual masses and positive PET scans
Numbers of types of tumour
Type of Biopsy FU
Patients NS S M follow up result months Category
12 8 4 – biopsy as original 18–66 TP
histology
5 2 2 1 clinical – 22–66 TP
response to therapy
5 3 2 – clinical – 18–30 TP
progressive disease
3 3 – – clinical – <3 TP
died rapidly from disease
1 – 1 – microbiology – amoebic abscess 36 FP
NS = nonseminomatous disease; S = seminoma; M = mixed; TP = true positive; FP = false positive
Figure 1 CT scan of the groin in a patient following chemotherapy and
retroperitoneal radiotherapy for seminoma. The CT shows a node in the left
groin but is unable to distinguish viable tumour from fibrosis
a
b
Figure 2 The PET scan of the patient in Figure 1 clearly showing 18FDG
accumulation in the left groin node. Biopsy showed this mass to contain
seminoma(Figs 1 and 2) and there was one false positive scan
(Table 1). This was found in a patient who had an amoebic abscess
in the liver which was clinically suspected before FDG PET scan-
ning and appropriate antibiotic therapy was given with resolution
of the abscess.
FDG PET negative patients
Twenty-one of the 47 scans were negative with eight of these true
negative scans (Figs 3 and 4) and 3 false negatives (Table 2). Two
patients had very small areas of malignancy in large masses of
fibrosis or MTD. The other false negative was in a patient who had
undergone PET scanning within 10 days of chemotherapy and this
patient had seminoma found on biopsy.
The sensitivity and specificity for FDG PET in residual masses
is shown in Table 3.
Marker positive patients
Forty-one FDG PET scans were performed in patients with
elevated markers of which 18 scans were performed in patients
with both raised markers and residual masses.
FDG PET positive scans
Twenty-eight of the 41 scans performed were positive (Table 4).
Twelve of these were in patients who had raised markers alone and
sixteen in patients with residual masses and markers that were
raised. Twenty-seven of these scans were true positive scans
and one was a false positive in a patient with histologically
confirmed MTD.
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Figure 3 CT guided biopsy of retroperitoneal lymph node where CT was
unable to confirm malignancy. The biopsy was inconclusive
Figure 4 The PET scan of the patient in Fig. 3 showing no abnormal 18FDG
uptake. Laparotomy showed the node to contain fibrosis only
Table 2 Patients with residual masses and negative PET scans
Patients Type of Tumour type Biopsy FU
follow up NS S M result months Category
6 clinical 2 2 2 none 18–66 TN
6 biopsy – 6 – negative 18–73 TN
6 biopsy 4 2 – non-malignant 18–66
pathology (MTD in 1) TN
1 biopsy 1 – – MTD + 54 FN
NSGCT
1 biopsy 1 – – fibrosis + 48 FN
NSGCT
1 biopsy – 1 – Seminoma 54 FN
MTD = mature differentiated teratoma; S = seminoma; NS = nonseminomatous germ cell tumour; M = mixed; TN = true negative; FN = false negative
AB
Figure 5 A patient with raised markers and normal CT had a normal PET
scan (A). The markers continued to rise, the CT remained normal and the
PET scan was the first imaging technology to identify the site of the disease
(arrow) (B)FDG PET negative scans
Thirteen of forty-one FDG PET scans were negative in patients
with elevated markers (Table 5). Seven scans were true negatives
and 6 were false negatives. Two patients had a small area of
malignant disease, one in a large mass of MTD and one in a
fibrotic mass. The other four developed progressive disease within
1–4 months and in three of these PET was the first imaging
modality to identify the site and presence of disease (Fig. 5). The
4th patient did not have a subsequent PET scan.
The overall value in terms of sensitivity, specificity and nega-
tive and positive predictive value of markers etc. is demonstrated
in Table 3.
Management alteration in all patients
The pre FDG PET plan of management based on the CT findings
for the patients were compared with the post PET management
which should have occurred with either upgrading or downgrading
of disease in the group presenting with residual masses. Twenty-
seven (5 seminoma, 20 NSGCT, 2 mixed) of the 47 patients had a
change in management as a result of the FDG PET scan. These
changes are shown in Table 6.
DISCUSSION
Traditionally the staging of testicular cancer both at diagnosis and
follow up has involved clinical evaluation, CT scanning and
marker measurements. It has been recognized that the use of CT
for disease assessment is inherently flawed since tumour may be
present in ‘normal’ sized lymph nodes (Saunders et al, 1999) and
large masses may contain no tumour. Also tumour markers may be
elevated for reasons other than the presence of tumour. These
confounding factors following the initial treatment of disease lead
to difficulties in deciding whether residual masses contain necrotic
tissue, fibrosis, mature teratoma or persistent disease. The latter
may need immediate surgical resection but mature differentiated
teratoma removal could be delayed and undertaken as a planned
procedure with reduction in patient morbidity. Since CT is not able
to provide this information for patients with residual masses
various functional imaging modalities have been explored and
newer techniques such as FDG PET imaging are also being
evaluated (de Wit et al, 1997; Bangerter et al, 1998).
There have been few reports of the use of FDG PET in this area.
Stephens et al (1996) studied 30 patients with NSGCT with
masses post chemotherapy and found that FDG PET was useful to
define which patients needed to proceed to surgery. FDG PET did
not however distinguish MTD from necrosis or fibrosis, but it did
differentiate viable tumour from the other three. This has been
confirmed by other studies (Muller-Mattheis et al, 1998) although
Sugwara et al (1999) found that the use of kinetic rate constants
may differentiate MTD from the other two. Cremerius et al (1998)
evaluated 42 post treatment scans (13 within 2 weeks of
chemotherapy and 29 more than 2 weeks after chemotherapy) and
showed that FDG PET had an accuracy of 90% in determining the
presence of active seminoma, providing the scans were performed
more than two weeks after chemotherapy. Overall they found FDG
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Table 3 Relative sensitivity, specificity, accuracy and predictive values for PET in the various groups of patients studied (n = number of scans)
Sensitivity Specificity Accuracy PPV NPV
CT with 56
residual masses
PET with
residual masses 88 95 91 96 90
n = 47
PET with
elevated markers 71 83 74 92 50
alone n = 23
PET in all scans 81 92 86 95 75
n = 70
markers in all scans 76 70 74 80 66
n = 70
markers in scans for 62 95 76 94 66
residual masses
n = 47
FDG PET scan
Positive Negative
Negative
Markers
Appropriate
further therapy
Positive
Markers
FDG PET scan
1—3 months
Positive Negative
Appropriate
further therapy
Surveillance
Surveillance
Patient with elevated markers or residual mass following therapy for
germ cell tumours
Figure 6 A algorithm for the use of 18FDG-PET scanning in patients with
residual masses or elevated markersPET to be superior to CT in the assessment of residual masses and
postulated that this could have an effect on patient management.
Ganjoo et al (1999) reviewed a smaller number of patients (29
patients) with seminoma in which PET was correctly negative in
19 post initial chemotherapy. In 10 patients who were scanned post
salvage chemotherapy 5 patients were correctly negative and 5
relapsed several months later in a PET negative site. None of these
5 patients had PET performed close to the time of relapse and it is
difficult to determine from the methods of scanning whether a
localized transmission scan was performed over the residual mass.
The methods use an arbitrary semiquantitative measure as a cut off
for determining disease presence which may also be inaccurate.
The present study shows that FDG PET alone has a good sensi-
tivity and specificity (88 and 95% respectively) for detecting
residual disease in masses and also a high negative and positive
predictive value (90 and 96%). This compares favourably with the
values for sensitivity and specificity of markers in masses (62 and
95%); the negative predictive value of markers however is low at
66%. It is particularly important to note that there were only two
false positive scans. One in a patient with a known amoebic
abscess which did not provide any source for confusion in the
patient management as it is also well known that infective lesions
can be visualized with FDG PET scanning (O’Doherty et al,
1997). The other was in a patient with MTD which was surprising
since the majority of the MTD lesions were negative on FDG
PET. There was no adequate explanation from the histological
appearance of the positive finding.
MTD was otherwise found to have no FDG uptake which would
be expected since it is essentially a benign condition with a low
metabolic rate. These masses do however have the potential to
become malignant and are generally removed surgically. The
morbidity is higher if the patients are operated on immediately
post chemotherapy or radiotherapy especially in those patients
with serious comorbid conditions. This finding of a reduced
uptake agrees with those of other investigators (Stephens et al,
1996), although Cremerius et al (1998) believed the finding to be a
false negative result.
The positive predictive value in masses is extremely high and
allows a high degree of certainty with which to decide which
patients need further treatment. It may not be felt this detection of
malignant residual disease is important in the management of
NSGCT; where removal of benign MTD is routinely advised,
however, early detection of persistent disease could allow
early scheduling of salvage surgery with possible benefits to
outcome.
Detection of active disease may be more important in semi-
noma. Relapses in residual masses occur; but surgical removal is
difficult and there is no clear advantage of routine
postchemotherapy radiotherapy (Duchesne et al, 1997). Close CT
follow up is advised. Use of FDG PET scanning could be helpful
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Table 4 Patients with elevated markers and positive PET scans. The patients had either elevated markers alone (CT –ve) or elevated markers with a mass
(CT +ve)
No of type of tumour
CT Biopsy FU
Patients NS S M Type of follow up finding result months Category
4 1 – 3 biopsy –ve positive 18–36 TP
1 1 biopsy –ve MTD 66 FP
5 4 – 1 clinical-response to therapy –ve none 18–24 TP
1 1 clinical-MRI confirmed disease –ve none 18 TP
-therapy response
1 1 progressive disease –ve none 18 TP
16 5 1 – biopsy +ve 18–66 TP
3 1 1 clinical-response to therapy +ve 22–66 TP
4 1 – clinical-died/progressive disease +ve <3–24 TP
NS = non-seminoma; S = seminoma; M = mixed; MTD = mature teratoma; TP = true positive; FP = false positive
Table 5 Patients with elevated markers and negative PET scans
Tumour types
Type of CT Biopsy FU PET
Patients NS S M follow up finding result months category
7 4 2 1 clinical –ve – 18–66 TN
2 2 biopsy +ve small area of teratoma FN
in MTD or fibrosis 30–36
4a 2 2 clinical-progressive disease –ve 18–19 FN
MTD = mature differentiated teratoma; NSGCT = nonseminomatous germ cell tumour; TN = true negative; FN = false negative. aIn three of these patients PET
was subsequently positive and was the first imaging modality to demonstrate the site of disease
Table 6 Management changes based on FDG PET scan findings
(XRT = radiotherapy)
Post FDG PET scan therapy
Pre PET therapy Chemotherapy Surgery Clinical
decision No. XRT Follow-up
Chemotherapy 12 – 5 7
Surgery/XRT 15 8 – 7
Clinical – – – –in this setting to identify patients who could then be treated by
radiotherapy.
A negative FDG PET in patients with masses was predictive of
the absence of disease, although false negatives did occur. The false
negative results were of interest for a number of reasons. One of the
false negative results occurred in a patient in whom the scan was
performed within 10 days of finishing chemotherapy. Cremerius et
al (1998) found a large number of patients who had false negative
scans performed within two weeks of chemotherapy. The mecha-
nism for this is uncertain and whether this is a treatment related
problem remains to be seen and certainly needs further investiga-
tion. It would seem reasonable not to scan within two weeks of
chemotherapy in patients with germ cell tumours. The other two
false negative results were more concerning since each were due to
small volumes of malignancy in large MTD masses. Ganjoo et al
(1999) also found 5 patients who relapsed in a residual seminoma
mass several months post negative PET scan and the assumption
must be that there must have been at least a few malignant cells in
the mass at the time of PET scanning. The mass of malignancy
detected by FDG PET imaging would be expected to vary
depending on the tumour type and metabolic activity. Any imaging
procedure is going to have a detection limit but it is possible that the
timing of the scan post FDG injection may be an issue in detecting
smaller volumes of disease (Lodge et al, 1999). The negative predic-
tive value with standard scanning times is high and is reassuring in
most circumstances.
Tumour markers are important in the follow up of patients, and
may be the first indicator of relapse (Rathmall et al, 1993).
Unfortunately marker negative relapse can occur, even when
markers are positive at presentation, also some patients with
residual masses can have modest elevations of markers after
chemotherapy even though the patients only have necrosis or
MTD (Coogan et al, 1997). Similarly a return to normal in
elevated markers following treatment does not necessarily corre-
late with disease remission. (Mostofi et al, 1990; Javadpour,
1992). In tumour marker positive patients there are two areas of
difficulty. Firstly when there are multiple residual masses which if
any contain malignant disease. Secondly in patients with no
residual mass, where if anywhere is the malignancy located and
what therapy is required.
In the patients who were marker positive all but one of the PET
scans that were positive identified disease. In the group with raised
markers alone when FDG PET was positive all scans were true
positives 12/12, but when markers were raised in patients with
residual masses 15/16 were true positive and only 1/16 false posi-
tive suggesting that the combination of a positive FDG PET and
positive markers was diagnostic of disease recurrence. FDG PET
allowed the identification of the site of disease in these patients.
Previous studies using FDG PET could not reach any conclusion
with regard to patients with positive tumour markers since most
had not had these recorded at the time of scanning (Cremerius et
al, 1998). The negative scans were not as predictive of absence of
disease with five false negative scans, but in three of these patients
a subsequent PET scan was positive and was the only imaging
investigation to identify the site of disease. This identification
helped in deciding on the optimum management of these patients.
Comparing the use of markers and FDG PET scanning overall the
FDG PET results showed better results in sensitivity, specificity,
accuracy, negative and positive predictive values.
FDG-PET is both sensitive and specific for detecting relapse in
patients with germ cell tumour both in patients with raised markers
and residual masses. A possible algorithm for investigating
patients with germ cell tumours is illustrated in Figure 6. The
ability of FDG PET to identify more widespread disease than
conventional imaging resulted in a change in management of
approximately 57% of patients between local therapy
(surgery/radiotherapy) and chemotherapy or surveillance.
Although this may appear to be a high percentage of patients with
a need for management change, many of these patients had
complicated clinical courses and demonstrated chemo-resistance.
Thus local treatment is often the only hope of cure and the detec-
tion of involved sites becomes very important. In those with first
relapse whether there are a few or multiple sites will define the
type of consolidation treatment (further chemotherapy or local
radiotherapy) post salvage chemotherapy. These changes in
management illustrate the potential huge benefits to patients using
FDG PET imaging, although a cost effectiveness study needs to be
performed. Furthermore the use of FDG PET in the staging of
disease at initial presentation needs to be explored since this study
demonstrates that these tumours are FDG avid and that this
modality was the first to demonstrate disease sites when compared
to CT staging.
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